-
Mashup Score: 5Towards precision in defining COPD exacerbations - 3 year(s) ago
COPD is the most prevalent chronic respiratory disease worldwide and a major cause of disability and death. Acute exacerbations of COPD remain a key feature of the disease in many patients and research assessing interventions to prevent and treat them requires a robust definition with high sensitivity and specificity. To date, no such definition exists, and multiple different definitions are used…
Source: European Respiratory SocietyCategories: Latest Headlines, PulmonologyTweet
-
Mashup Score: 6Pulmonary Rehabilitation - 3 year(s) ago
Pulmonary rehabilitation is an effective treatment for people with a range of chronic lung diseases. In recent years, there have been substantial advances in the science underpinning pulmonary rehabilitation. Advances have been seen in the patient groups in whom it is indicated; in the breadth of programme content; in new methods of delivery; and not least, in important outcomes. This Monograph…
Source: European Respiratory SocietyCategories: Latest Headlines, PulmonologyTweet
-
Mashup Score: 5High serum granulocyte-colony stimulating factor characterises neutrophilic COPD exacerbations associated with dysbiosis - 3 year(s) ago
Introduction COPD exacerbations are heterogeneous and can be triggered by bacterial, viral, or noninfectious insults. Exacerbations are also heterogeneous in neutrophilic or eosinophilic inflammatory responses. A noninvasive peripheral biomarker of COPD exacerbations characterised by bacterial/neutrophilic inflammation is lacking. Granulocyte-colony stimulating factor (G-CSF) is a key cytokine…
Source: European Respiratory SocietyCategories: Latest Headlines, PulmonologyTweet
-
Mashup Score: 1Statins as adjunct therapy in COPD: is it time to target innate immunity and cardiovascular risk? - 3 year(s) ago
The main goal of management for COPD is to minimise symptoms and prevent exacerbations [1]. For patients with COPD, exacerbations are a major determinant of reduced quality of life, progressive decline in lung function and increased mortality, particularly from cardiovascular causes [1, 2]. Risk factors predicting future exacerbations include a prior exacerbation, increasing age, worsening lung…
Source: European Respiratory SocietyCategories: Latest Headlines, PulmonologyTweet
-
Mashup Score: 4Can simvastatin reduce COPD exacerbations? A randomised double-blind controlled study - 3 year(s) ago
Background Several studies have shown that statins have beneficial effects in COPD regarding lung function decline, rates and severity of exacerbation, hospitalisation and need for mechanical ventilation. Methods We performed a randomised double-blind placebo-controlled single-centre trial of simvastatin at a daily dose of 40 mg versus placebo in patients with Global Initiative for Chronic…
Source: European Respiratory SocietyCategories: Latest Headlines, PulmonologyTweet
-
Mashup Score: 0MULTI-PHACET: multidimensional clinical phenotyping of hospitalised acute COPD exacerbations - 3 year(s) ago
Background The generic term “exacerbation” does not reflect the heterogeneity of acute exacerbations of COPD (AECOPD). We utilised a novel algorithmic strategy to profile exacerbation phenotypes based on underlying aetiologies. Methods Patients hospitalised for AECOPD (n=146) were investigated for aetiological contributors summarised in a mnemonic acronym ABCDEFGX (A: airway virus; B: bacterial;…
Source: European Respiratory SocietyCategories: Latest Headlines, PulmonologyTweet-
Hospitalised #AECOPD present as complex multidimensional clinical phenotypes, often comprising multiple distinct aetiologies. Profiling AECOPDs according to their multifactorial aetiological components has important prognostic and therapeutic implications. https://t.co/uBpg7daQ2I https://t.co/hOpOW0RUW4
-
-
Mashup Score: 2Home parasternal electromyography tracks patient-reported and physiological measures of recovery from severe COPD exacerbation - 3 year(s) ago
Exacerbations of COPD remain a leading cause of emergency hospitalisations worldwide, and up to 28% of patients are readmitted within 30 days of discharge [1]. Recent analyses of more than 2.3 million COPD hospitalisations highlight the dynamic and time-dependent nature of readmission risk, which peaks within the first 72 h of discharge [2, 3]. Effective readmission prevention strategies remain…
Source: European Respiratory SocietyCategories: Latest Headlines, PulmonologyTweet-
Physiological phenotyping using daily home-based assessments reveals early improvement in load–capacity–drive imbalance following #AECOPD and feasibility of home parasternal electromyography measurement, which tracks symptoms, health status and spirometry https://t.co/R4jg0n6P3b https://t.co/AWwbyJ8l3n
-
-
Mashup Score: 11Cardiac biomarkers and long-term outcomes of exacerbations of COPD: a long-term follow-up of two cohorts - 3 year(s) ago
Background COPD patients often have cardiac comorbidities. Cardiac involvement at the time of a COPD exacerbation is associated with a high short-term mortality, but whether this influences long-term outcomes is unknown. We explored whether biomarkers of cardiac dysfunction at the time of a COPD exacerbation predict long-term outcomes. Methods Two prospective cohorts of patients admitted to…
Source: European Respiratory SocietyCategories: Latest Headlines, PulmonologyTweet
-
Mashup Score: 0COPD in the time of COVID-19: an analysis of acute exacerbations and reported behavioural changes in patients with COPD - 3 year(s) ago
Introduction The impact of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic and associated “lockdown” measures on acute exacerbations of chronic obstructive pulmonary disease (AECOPD) is unknown. We aimed to evaluate the change in AECOPD treatment frequency during the first 6 weeks of lockdown in the UK compared with 2019 and assess changes in self-reported behaviour and…
Source: European Respiratory SocietyCategories: Latest Headlines, PulmonologyTweet
-
Mashup Score: 0
The efficacy and safety of high flow nasal therapy (HFNT) in patients with acute hypercapnic exacerbation of chronic obstructive pulmonary disease (AECOPD) are unclear. Our aim was to evaluate the short-term effect of HFNT versus NIV in patients with mild-to-moderate AECOPD, with the hypothesis that HFNT is non-inferior to NIV on CO2 clearance after 2 h of treatment. We performed a multicenter,…
Source: Critical CareCategories: Critical Care, Latest HeadlinesTweet
#AECOPD carry high risk for long-term disability and death. As the search for a standardised measure continues, study investigators must ensure definitions are explicit and justified to better understand how to prevent and manage these episodes. https://t.co/vdFhomGpOn